Details der Publikation - Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

Purpose Impaired health-related quality of life (HRQoL) is associated with poor health outcomes in chronic obstructive pulmonary disease (COPD). The aim of this study was to determine health utilities in patients with COPD and to identify the variables with the greatest impact. Methods This is a pooled analysis of data from 4 observational studies performed in stable COPD patients. Evaluation of patient HRQoL utilities was performed using the Spanish version of the self-administered EuroQoL 5 Dimensions (EQ-5D) questionnaire. EQ-5D utilities were described and compared according to several markers of disease severity. Results 6198 patients reported a mean (SD) EQ-5D index of 0.67 (0.26). A linear dose response relationship between EQ-5D utility and modified Medical Research Council (mMRC) score, forced expiratory volume in one 1 s (% predicted), COPD hospital admissions in the previous year, self-reported daily walking time, Charlson index, body mass index, obstruction, dyspnoea and exacerbation (BODEx) index, COPD assessment test (CAT), hospital anxiety and depression scale was observed (p for trend < 0.001). In multivariate analysis, patients reporting lower utility values were those with more dyspnoea, more comorbidities, using long-term oxygen therapy, with previous hospitalisations due to a COPD exacerbation and higher (worse) CAT score. Conclusion HRQoL measures such as EQ-5D can assist clinicians to understand the impact of respiratory disease on COPD patients..

Medienart:	E-Artikel

Erscheinungsjahr:	2019
Erschienen:	2019

Enthalten in:	Zur Gesamtaufnahme - volume:29
Enthalten in:	Quality of life research - 29(2019), 3 vom: 31. Okt., Seite 607-617

Sprache:	Englisch

Beteiligte Personen:	Esquinas, Cristina [VerfasserIn] Ramon, Maria A. [VerfasserIn] Nuñez, Alexa [VerfasserIn] Molina, Jesús [VerfasserIn] Quintano, José A. [VerfasserIn] Roman-Rodríguez, Miguel [VerfasserIn] Naberan, Karlos [VerfasserIn] Llor, Carl [VerfasserIn] Roncero, Carlos [VerfasserIn] Miravitlles, Marc [VerfasserIn] Barrecheguren, Miriam [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

BKL:	44.52$jTherapie$XMedizin
Themen:	CAT COPD EQ-5D Health-Related Quality of Life

Anmerkungen:	© Springer Nature Switzerland AG 2019

doi:	10.1007/s11136-019-02340-4

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2082727491

Internformat


LEADER	01000caa a22002652 4500
001	OLC2082727491
003	DE-627
005	20230504020814.0
007	cr uuu---uuuuu
008	230228s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11136-019-02340-4 \|2 doi
035			\|a (DE-627)OLC2082727491
035			\|a (DE-He213)s11136-019-02340-4-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 100 \|q VZ
084			\|a 5,1 \|2 ssgn
084			\|a PHILOS \|q DE-12 \|2 fid
084			\|a 44.52$jTherapie$XMedizin \|2 bkl
100	1		\|a Esquinas, Cristina \|e verfasserin \|4 aut
245	1	0	\|a Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Springer Nature Switzerland AG 2019
520			\|a Purpose Impaired health-related quality of life (HRQoL) is associated with poor health outcomes in chronic obstructive pulmonary disease (COPD). The aim of this study was to determine health utilities in patients with COPD and to identify the variables with the greatest impact. Methods This is a pooled analysis of data from 4 observational studies performed in stable COPD patients. Evaluation of patient HRQoL utilities was performed using the Spanish version of the self-administered EuroQoL 5 Dimensions (EQ-5D) questionnaire. EQ-5D utilities were described and compared according to several markers of disease severity. Results 6198 patients reported a mean (SD) EQ-5D index of 0.67 (0.26). A linear dose response relationship between EQ-5D utility and modified Medical Research Council (mMRC) score, forced expiratory volume in one 1 s (% predicted), COPD hospital admissions in the previous year, self-reported daily walking time, Charlson index, body mass index, obstruction, dyspnoea and exacerbation (BODEx) index, COPD assessment test (CAT), hospital anxiety and depression scale was observed (p for trend < 0.001). In multivariate analysis, patients reporting lower utility values were those with more dyspnoea, more comorbidities, using long-term oxygen therapy, with previous hospitalisations due to a COPD exacerbation and higher (worse) CAT score. Conclusion HRQoL measures such as EQ-5D can assist clinicians to understand the impact of respiratory disease on COPD patients.
650		4	\|a COPD
650		4	\|a Health-Related Quality of Life
650		4	\|a EQ-5D
650		4	\|a CAT
700	1		\|a Ramon, Maria A. \|4 aut
700	1		\|a Nuñez, Alexa \|4 aut
700	1		\|a Molina, Jesús \|4 aut
700	1		\|a Quintano, José A. \|4 aut
700	1		\|a Roman-Rodríguez, Miguel \|4 aut
700	1		\|a Naberan, Karlos \|4 aut
700	1		\|a Llor, Carl \|4 aut
700	1		\|a Roncero, Carlos \|4 aut
700	1		\|a Miravitlles, Marc \|4 aut
700	1		\|a Barrecheguren, Miriam \|4 aut
773	0	8	\|i Enthalten in \|t Quality of life research \|d Springer International Publishing, 1992 \|g 29(2019), 3 vom: 31. Okt., Seite 607-617 \|h Online-Ressource \|w (DE-627)320474399 \|w (DE-600)2008960-0 \|w (DE-576)121191001 \|x 1573-2649 \|7 nnns
773	1	8	\|g volume:29 \|g year:2019 \|g number:3 \|g day:31 \|g month:10 \|g pages:607-617
856	4	0	\|u https://dx.doi.org/10.1007/s11136-019-02340-4 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-PHILOS
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_187
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_2938
912			\|a GBV_ILN_2949
912			\|a GBV_ILN_2950
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4346
912			\|a GBV_ILN_4392
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
936	b	k	\|a 44.52$jTherapie$XMedizin \|q VZ \|0 10641593X \|0 (DE-625)10641593X
951			\|a AR
952			\|d 29 \|j 2019 \|e 3 \|b 31 \|c 10 \|h 607-617

Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände